Studies concerning the pathogenesis of VPA-induced hyperammonemia and subsequent encephalopathy have been previously reported.[3,5,15–17] VPA inhibits carbamoyl phosphate synthetase I, the key enzyme in the process of converting ammonia into urea in the liver, which leads to a toxic level of blood ammonia. The gene discussed is CPS1; the disease is Hyperammonemia.